Moxifloxacin

Manufactured by Meilun

Sourced in China

Moxifloxacin is a fluoroquinolone antibiotic used in the laboratory setting. It is a broad-spectrum antimicrobial agent that inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial cell division and replication.

Automatically generated - may contain errors

Lab products found in correlation

Levofloxacin, by Meilun (2 mentions) Cefazolin, by Meilun (1 mentions) Clindamycin, by Meilun (1 mentions) Linezolid, by Meilun (1 mentions) Glucose 6 phosphate (g6p), by Merck Group (1 mentions) Erythromycin, by Meilun (1 mentions) Daptomycin, by Meilun (1 mentions) Vancomycin, by Meilun (1 mentions) Amikacin, by Meilun (1 mentions) Tetracycline, by Meilun (1 mentions) Tigecycline, by Meilun (1 mentions) Oxacillin, by Meilun (1 mentions) Ciprofloxacin, by Meilun (1 mentions)

2 protocols using moxifloxacin

Antibiotic Susceptibility Testing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibiotic agents (oxacillin, cefazolin, cefuroxime, clindamycin, erythromycin, levofloxacin, moxifloxacin, tetracycline, tigecycline, amikacin, fosfomycin, trimethoprim-sulfamethoxazole, linezolid, vancomycin, daptomycin, rifampin) were purchased from Dalian Meilun Biotech (Dalian, China). Glucose-6-phosphate was obtained from Sigma-Aldrich Co. (St Louis, MO, USA). tigecycline and daptomycin susceptibility test were done via broth dilution method according to CLSI recommendations. The MICs of the other 15 antibiotics were determined using the twofold serial agar dilution method.9
E. faecalis ATCC 29212 were used as quality-control strains.

Chen M., Pan H., Lou Y., Wu Z., Zhang J., Huang Y., Yu W, & Qiu Y. (2018). Epidemiological characteristics and genetic structure of linezolid-resistant Enterococcus faecalis. Infection and Drug Resistance, 11, 2397-2409.

+ Open protocol

+ Expand

Antimicrobial Susceptibility Testing of Mycoplasma spp.

Check if the same lab product or an alternative is used in the 5 most similar protocols

In this study, 11 antimicrobials were used, including: Nemonoxacin (manufactured by Zhejiang Medicine Co., Ltd., Zhejiang, China), macrolides (erythromycin, roxithromycin, azithromycin, and josamycin), tetracyclines (tetracycline, minocycline, and doxycycline), and fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) (Dalian Meilun Biotech Co., China). All agents were obtained in powdered form of known purity and diluted according to their respective manufacturer’s instructions. The broth microdilution method was performed and the minimal inhibitory concentration (MIC) was defined according to Clinical and Laboratory Standards Institutes (Waites et al., 2011 ).
The minimum bactericidal concentrations (MBCs) for nemonoxacin was determined as previously described (Waites et al., 2017a (link)), which included 11 M. pneumoniae isolates, 5 M. hominis isolates, and 5 Ureaplasma spp. isolates. The positive and negative controls consisted of tetracycline (bacteriostatic) and moxifloxacin (bactericidal), respectively. When the MBC was ≥3 dilutions (eightfold) greater than the MIC, the drug was considered bacteriostatic. MBCs that were ≤2 dilutions (fourfold) greater than the MIC were considered bactericidal.

Wang N., Liu W., Zhou Y, & Liu Y. (2019). In vitro Activities of Nemonoxacin and Other Antimicrobial Agents Against Human Mycoplasma and Ureaplasmas Isolates and Their Defined Resistance Mechanisms. Frontiers in Microbiology, 10, 1890.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!